A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy.
To investigate the efficacy and safety of a study drug called baricitinib when used to treat severe active Rheumatoid Arthritis (RA) in those with inadequate response to Methotrexate.
Moderate to Severe Active Rheumatoid Arthritis (RA)
Males and Females, age 18 and older, with RA who are currently taking and having an inadquate response to methotrexate
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participation could last up to 62 weeks - with the possibility of entering a long-term extension study.
Eli Lilly & Company
Subjects will receive $42 for each study visit completed. If they complete the entire study they could receive up to $672.